Alzheimer’s Disease And Dementia

Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults

Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults

By

Using the Visual Association Test along with the Mini Mental State Examination may improve predictive value to screen for cognitive deficits.

<i>APOE</i> Status May Modulate Neurodegeneration Risk Based on Sex

APOE Status May Modulate Neurodegeneration Risk Based on Sex

By

The investigators analyzed specific AD biomarkers, including β-amyloid 42, total tau, and phosphorylated tau measured in CSF.

Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients

Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients

By

The findings from the study are limited in generalizability to the dementia-free patient population.

Genetic Risk Score Better Than APOE Alone for Assessing Risk for Alzheimer's Dementia

Genetic Risk Score Better Than APOE Alone for Assessing Risk for Alzheimer's Dementia

By

The genetic risk score primarily modified the risk for and onset of dementia and AD among homozygous carriers for APOE ε4.

High Amyloid Beta, Independent of Tau, Is Associated With Risk for Cognitive Decline

High Amyloid Beta, Independent of Tau, Is Associated With Risk for Cognitive Decline

By

Preclinical AD stages 1 and 2 demonstrated higher rates of linear cognitive decline with age, particularly with regard to story memory and processing speed measures.

Excessive Sleepiness Associated With Increased Aβ Accumulation in Elderly Without Dementia

Excessive Sleepiness Associated With Increased Aβ Accumulation in Elderly Without Dementia

By

This study predominantly relied on a subjective patient reporting system to assess sleep disturbances, which may have limited the findings.

β-amyloidosis Alone is an Unreliable Predictor of Alzheimer Disease Progression

β-amyloidosis Alone is an Unreliable Predictor of Alzheimer Disease Progression

By

Only 4 patients had progressed to clinical AD during the follow-up period, all of whom rated positive for amyloid β deposition.

Assessing Parental Symptom Onset Proximity in Alzheimer Disease

Assessing Parental Symptom Onset Proximity in Alzheimer Disease

By

Investigators evaluated CSF Aβ1-42 levels obtained from individuals who presented no signs of cognitive dysfunction at enrollment and estimated the proximity of participants' age to their parents' age of AD symptom onset.

Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life

Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life

By

The investigators hope that the findings from the study help raise awareness of frontotemporal dementia in geriatric patients.

Long-Term Forgetting May Identify Alzheimer Disease Symptoms Before Onset

Long-Term Forgetting May Identify Alzheimer Disease Symptoms Before Onset

By

The investigators assessed the amount of material retained at 30 minutes and compared this with material recalled at 7 days.

Short-Term Benefit for Alzheimer Disease Psychosis With Pimavanserin

Short-Term Benefit for Alzheimer Disease Psychosis With Pimavanserin

By

Despite its short-term efficacy, pimavanserin provided no significant benefit in the overall cohort for improving psychotic symptoms at 12 weeks of treatment when compared with placebo.

Investigators Discover Efficient Plasma Biomarkers for Predicting Amyloid-β Burden in Dementia

Investigators Discover Efficient Plasma Biomarkers for Predicting Amyloid-β Burden in Dementia

By

Accuracy of the composite biomarker for predicting brain amyloid-β burden was 90% with the use of 11C-labelled Pittsburgh compound-B-PET as a standard of truth.

Amyloid Deposition May Be Reversed With <i>BACE1</i> Inhibition

Amyloid Deposition May Be Reversed With BACE1 Inhibition

Sequential, increased deletion of BACE1 in an adult mouse model of Alzheimer disease reversed amyloid deposition.

Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease

Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease

By

The 400 mg solanezumab dose used in this study may not have been sufficient enough to provide clinically meaningful effects in these patients.

Factors Predictive of Mild Cognitive Impairment in Healthy Individuals

Factors Predictive of Mild Cognitive Impairment in Healthy Individuals

By

Investigators sought to examine factors that influence a cognitively normal individual's risk for developing symptoms of mild cognitive impairment due to Alzheimer disease.

Increased Midlife Triglyceride Levels Predictive of Alzheimer Disease Pathology

Increased Midlife Triglyceride Levels Predictive of Alzheimer Disease Pathology

By

If confirmed in future studies, high triglycerides may present a modifiable risk factor for Alzheimer disease.

Proton Pump Inhibitor Use Not Associated With Increased Dementia Risk

Proton Pump Inhibitor Use Not Associated With Increased Dementia Risk

By

A population-based cohort study evaluated whether proton pump inhibitor use was associated with an increased risk for dementia.

When and How to Approach Driving Cessation in Patients With Dementia

When and How to Approach Driving Cessation in Patients With Dementia

By

The responsibility for discussing cessation of driving in patients with mild cognitive impairment or dementia often rests on the clinician, who may have little preparation for this difficult conversation.

Language Deficits and EEG Changes Predict Conversion From MCI to Alzheimer Disease

Language Deficits and EEG Changes Predict Conversion From MCI to Alzheimer Disease

By

Participants with MCI who developed Alzheimer disease at 3 years were more likely to demonstrate diminished theta increase on EEG compared with patients who did not develop the disease.

Alzheimer Disease Drug Candidate Granted Fast Track Status

Alzheimer Disease Drug Candidate Granted Fast Track Status

By

The FDA has granted Fast Track designation to ALZ-801 for the treatment of Alzheimer disease.

Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly

Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly

By

Zolpidem has been associated with memory loss and decline in cognitive function.

Androgen Deprivation Therapy Does Not Increase Dementia or Alzheimer Risk

Androgen Deprivation Therapy Does Not Increase Dementia or Alzheimer Risk

By

Previous research has suggested an association between androgen deprivation therapy and risk for Alzheimer dementia.

Dementia Risk Significantly Increased for Individuals Born in High Stroke Mortality States

Dementia Risk Significantly Increased for Individuals Born in High Stroke Mortality States

By

Birthplace is a significant risk factor for dementia, even after adjusting for educational levels, race, and life-course vascular risk factors.

Can Proton Pump Inhibitors Raise Dementia Risk?

Can Proton Pump Inhibitors Raise Dementia Risk?

Those who used PPIs were also more likely to use anticholinergic medicines that have been linked to cognitive difficulties

Degree of Amyloid Deposition Helps Predict Cognitive Decline

Degree of Amyloid Deposition Helps Predict Cognitive Decline

By

The main differentiating factor was the presence of the APOE ε4 allele.

Growing Old Without Alzheimer's Pathology: What's the Secret?

Growing Old Without Alzheimer's Pathology: What's the Secret?

By

The main differentiating factor was the presence of the APOE ε4 allele.

Discontinuation of Alzheimer's Treatment Linked to Adverse Events

Discontinuation of Alzheimer's Treatment Linked to Adverse Events

Adverse events were related to over 73% of medication discontinuations.

Serum Cytokine Levels May Correlate With Cognitive Dysfunction in Alzheimer's Disease

Serum Cytokine Levels May Correlate With Cognitive Dysfunction in Alzheimer's Disease

By

Patients with Alzheimer's disease may have higher serum IL-6 levels than subjects with mild cognitive impairment and healthy controls.

Alzheimer's Mortality Increasing, But So Is At-Home Care

Alzheimer's Mortality Increasing, But So Is At-Home Care

More patients are dying at home as opposed to in nursing home facilities, suggesting increased support for caregivers is necessary.

Neuropsychiatric Symptoms May Be a Marker of Preclinical Alzheimer's

Neuropsychiatric Symptoms May Be a Marker of Preclinical Alzheimer's

By

Sleep behavior and irritability may be early noncognitive symptoms of Alzheimer's dementia.

Sign Up for Free e-newsletters



CME Focus